Table 1

Clinical characteristics of the 80 patients with axial spondyloarthritis (axSpA) included in the study

CharacteristicSpA (n=80)
Female n (%)25 (31%)
Median (IQR) age at sampling (years)37 (19–64)
Median (IQR) disease duration (years)2 (0–33)
HLA-B27 positive n (%)63 (79%)
Current smokers n (%)40 (50%)
Median (IQR) C reactive protein (CRP) (mg/L) at baseline6.06 (0.09–62)
Median (IQR) BASDAI at baseline49.80 (9.40–90)
Median (IQR) ASDAS at baseline3.05 (1.13–4.79)
Axial involvement n (%)80 (100%)
Axial and enthesial involvement n (%)38 (47.5%)
Radiological sacroiliitis n (%)48 (60%)
MRI sacroiliitis n (%)63 (79%)
TNF blocker
Soluble TNF receptor etanercept n (%)53 (66.25%)
Monoclonal antibody adalimumab n (%)13 (16.25%)
Monoclonal antibody golimumab n (%)13 (16.25%)
Monoclonal antibody infliximab n (%)1 (1.25%)
Extra-articular manifestations
Psoriasis n (%)16 (20%)
Uveitis n (%)26 (33%)
IBD (%)3 (4%)
Response at D90
Median (IQR) CRP (mg/L) at D901.95 (0–51.80)
Median (IQR) BASDAI at D9023.50 (0–78)
Median (IQR) ASDAS at D901.44 (0.64–3.45)
Patients with major ASDAS improvement n (%)20 (25%)
Patients with clinically important improvement ASDAS n (%)30 (37.5%)
Non-responder ASDAS n (%)30 (37.5%)
Non-responder ASDAS treated with etanercept n (%)22 (73.33%) (41.5%)†
Non-responder ASDAS treated with adalimumab n (%)5 (16.67%) (38.5%)†
Non-responder ASDAS treated with golimumab n (%)3 (10%) (23.1%)†
Non-responder ASDAS treated with infliximab n (%)0 (0 %)
Non-responder BASDAI50 n (%)52 (65%)
  • Median and IQR or percentages are shown.

  • *Percentage of total non-responders.

  • †Percentage of patients treated with the indicated drug.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; IBD, inflammatory bowel disease; TNF, tumour necrosis factor.